antibody levels and vaccination attitude after asymptomatic to moderate

omniscientis

omniscientis

Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic

 

Regardless of substantial progress in confronting the worldwide HIV-1 epidemic since its inception within the 1980s, higher approaches for each therapy and prevention will probably be obligatory to finish the epidemic and stay a high public well being precedence. Antiretroviral remedy (ART) has been efficient in extending lives, however at a price of lifelong adherence to therapy. Broadly neutralizing antibodies (bNAbs) are directed to conserved areas of the HIV-1 envelope glycoprotein trimer (Env) and may block an infection if current on the time of viral publicity. The therapeutic software of bNAbs holds nice promise, and progress is being made towards their growth for widespread medical use. In comparison with the present customary of care of small molecule-based ART, bNAbs supply: (1) decreased toxicity; (2) the benefits of prolonged half-lives that might bypass day by day dosing necessities; and (3) the potential to include a wider immune response by Fc signaling. Latest advances in discovery expertise can allow system-wide mining of the immunoglobulin repertoire and can proceed to speed up isolation of subsequent era potent bNAbs. Passive switch research in pre-clinical fashions and medical trials have demonstrated the utility of bNAbs in blocking or limiting transmission and attaining viral suppression.

These research have helped to outline the window of alternative for optimum intervention to realize viral clearance, both utilizing bNAbs alone or together with ART. None of those advances with bNAbs can be doable with out technological developments and increasing the cohorts of donor participation. Collectively these components fueled the exceptional development in bNAb growth. Right here, we evaluation the event of bNAbs as therapies for HIV-1, exploring advances in discovery, insights from animal fashions and early medical trials, and improvements to optimize their medical potential by efforts to increase half-life, maximize the contribution of Fc effector capabilities, preclude escape by multiepitope concentrating on, and the potential for sustained supply.

 

Signs, antibody ranges and vaccination perspective after asymptomatic to reasonable COVID-19 an infection in 200 healthcare employees

 

Purpose: In Germany, the willingness to be vaccinated towards COVID-19 is slightly low amongst medical workers. We collected information on signs, antibody titers and vaccination readiness from clinic workers at a municipal clinic who had already been by a COVID-19 an infection (asymptomatic to reasonable). We additionally examined the antibody titers for his or her doable significance as a person decision-making assist with regard to vaccination.

 

Technique: 200 workers of our municipal clinics have been included within the research. COVID-19 antibody dedication was carried out utilizing an ELISA (EUROIMMUN™, PerkinElmer, Inc. Firm). The individuals got an nameless questionnaire containing anthropometrical points, signs of the an infection and questions in regards to the vaccination resolution. Lastly, the antibody ranges have been reported to the individuals and the perspective in the direction of a vaccination was reevaluated.

 

Outcomes: In all 200 individuals who had already gone by a COVID-19 an infection, 75 workers have been in favor of a vaccination (37.5%), 96 have been against vaccination (48%), and 29 have been undecided (14.5%). Within the completely different occupational teams, the constructive pattern by way of willingness to be vaccinated was highest amongst physicians and is least amongst nurses. The antibody outcomes confirmed appreciable variation in titer ranges and subsequently didn’t correlate with illness severity in asymptomatic to reasonably in poor health individuals. We additionally noticed a pro-vaccination pattern with rising age of the individuals. The specifically-asked symptom of cutaneous hyperesthesia throughout COVID-19 an infection occurred in 5% of the individuals.

 

Conclusion: In medical personnel who had already suffered from a COVID-19 an infection, the willingness to obtain a vaccination tends to be highest amongst physicians, and lowest in nurses, and will increase with age. For the overwhelming majority of these affected, data of the antibody titers solely reinforces the vaccination resolution made beforehand and thus doesn’t contribute to a change in vaccination resolution. The specifically-requested symptom of cutaneous hyperesthesia throughout COVID-19 an infection was unexpectedly frequent.

omniscientis
omniscientis

Recombinant Bothrops atrox Disintegrin batroxostatin

CSB-EP325595BUU 10062 mg Ask for price

Recombinant Bothrops atrox Thrombin-like enzyme batroxobin

CSB-EP356422BUU 11904 mg Ask for price

Recombinant Bothrops atrox Zinc metalloproteinase atroxlysin-1

CSB-EP307733BUU 10234 mg Ask for price

Recombinant Bothrops jararaca Zinc metalloproteinase-disintegrin-like botrocetin, partial

CSB-EP325199BUW 6923 mg Ask for price

Rabbit Anti-Snake VEGF-F

105-PA01 100ug
EUR 240

Snake Venom Phospholipase A2 Purified Lyophilized

IDBRPLA2LY1MG each
EUR 119
Description: Snake Venom Phospholipase A2 Purified Lyophilized

Snake Venom Phosphodiesterase I Purified Lyophilized

IDBRPDEILY100UN each
EUR 151
Description: Snake Venom Phosphodiesterase I Purified Lyophilized

Crotalus adamanteus Snake venom metalloproteinase adamalysin-2

1-CSB-EP330325DYB
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Crotalus adamanteus Snake venom metalloproteinase adamalysin-2 expressed in E.coli

Custom Testing of Samples for Antibodies Snake Venom (anti-venins from Horse/Sheep) by ELISA

570-100-CUX Custom Ask for price

Recombinant Crotalus atrox Snake venom serine protease catroxase-2

CSB-YP854470DYC 6937 mg Ask for price

Recombinant Crotalus atrox Snake venom serine protease catroxase-2

CSB-BP854470DYC 7642 mg Ask for price

Recombinant Crotalus atrox Snake venom serine protease catroxase-2

RPC27424-100ug 100ug
EUR 1544.5

Recombinant Crotalus atrox Snake venom serine protease catroxase-2

RPC27424-1mg 1mg
EUR 3933.6

Recombinant Crotalus atrox Snake venom serine protease catroxase-2

RPC27424-20ug 20ug
EUR 580.8

Recombinant Crotalus atrox Snake venom serine protease catroxase-2

RPC28372-100ug 100ug
EUR 863.2

Recombinant Crotalus atrox Snake venom serine protease catroxase-2

RPC28372-1mg 1mg
EUR 3462

Recombinant Crotalus atrox Snake venom serine protease catroxase-2

RPC28372-20ug 20ug
EUR 479.6

Recombinant Crotalus adamanteus Snake venom metalloproteinase adamalysin-2

AP77219 1mg
EUR 2826

Recombinant Crotalus adamanteus Snake venom metalloproteinase adamalysin-2

CSB-EP330325DYB 2971 mg Ask for price

Recombinant Crotalus adamanteus Snake venom metalloproteinase adamalysin-2

RPC22529-100ug 100ug
EUR 721.6

Recombinant Crotalus adamanteus Snake venom metalloproteinase adamalysin-2

RPC22529-1mg 1mg
EUR 2884.7

Recombinant Crotalus adamanteus Snake venom metalloproteinase adamalysin-2

RPC22529-20ug 20ug
EUR 448.1

Naja mossambica Snake venom metalloproteinase-disintegrin-like mocarhagin

1-CSB-EP606027NAH
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Naja mossambica Snake venom metalloproteinase-disintegrin-like mocarhagin expressed in E.coli

Recombinant Naja mossambica Snake venom metalloproteinase-disintegrin-like mocarhagin

AP74342 1mg
EUR 2826

Recombinant Naja mossambica Snake venom metalloproteinase-disintegrin-like mocarhagin

CSB-EP606027NAH 3683 mg Ask for price

anti- VEGF antibody

FNab09391 100µg
EUR 658.5
Description: Antibody raised against VEGF

Anti- VEGF antibody

FNab09933 100µg
EUR 658.5
Description: Antibody raised against VEGF

Anti-Human VEGF

GWB-BIG9B7 500ug Ask for price

Anti-VEGF/VEGF164 Antibody

A00045-1 100ug/vial
EUR 352.8

Anti-VEGF Antibody Clone VEGF/1063, Unconjugated-100ug

7422-MSM1-P1 100ug
EUR 513.6

VEGF-A(VEGF/1063) Antibody

BNC811063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC811063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC801063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC801063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC431063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC431063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC051063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC051063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC551063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC551063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC701063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC701063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC611063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNC611063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCP1063-250 250uL
EUR 459.6
Description: Primary antibody against VEGF-A(VEGF/1063), PerCP conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCR1063-250 250uL
EUR 459.6
Description: Primary antibody against VEGF-A(VEGF/1063), RPE conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCA1063-250 250uL
EUR 459.6
Description: Primary antibody against VEGF-A(VEGF/1063), APC conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCH1063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCH1063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCAP1063-100 100uL
EUR 238.8
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

VEGF-A(VEGF/1063) Antibody

BNCAP1063-500 500uL
EUR 652.8
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Anti-Rat VEGF Antibody

TA328599 100 µg Ask for price

Anti-VEGF/Vegfa Antibody

A00045 100ug/vial
EUR 352.8

Anti-VEGF/Vegfa Antibody

A00045-2 100ug/vial
EUR 352.8

Anti-VEGF/VEGFA Antibody

PB9071 100ug/vial
EUR 400.8

VEGF-F / svVEGF rabbit polyclonal antibody, Purified

AP26033PU-L 200 µg Ask for price

VEGF-F / svVEGF rabbit polyclonal antibody, Purified

AP26033PU-N 100 µg Ask for price

Rabbit anti VEGF-C (rat)

104-PA10S 100ug
EUR 240

Rabbit anti VEGF-D (rat)

104-PA12 100ug
EUR 240

VEGF Rabbit Polyclonal Antibody(VEGF)

RA20266-100ul 100 ul
EUR 298

VEGF Rabbit Polyclonal Antibody(VEGF)

RA20266-50ul 50 ul
EUR 198

Anti-Rat VEGF-A Antibody

104-P15 100 µg
EUR 245.7
Description: Rat VEGF (or VEGF-A) is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothellial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase(flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant rat VEGF (isoform 164) is a 38.5 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains.

Anti-Rat VEGF-C Antibody

104-PA10 200 µg
EUR 157.5
Description: VEGF-C, a member of the VEGF/PDGF family of structurally related proteins, is a potent angiogenic cytokine. It promotes endothelial cell growth, promotes lymphangiogesis, and can also affect vascular permeability. VEGF-C is expressed in various tissues, but is not produced in peripheral blood lymphocytes. It forms cell surfaced-associated non-covalent disulfide linked homodimers, and can bind and activate both VEGFR-2 (flk1) and VEGFR-3 (flt4) receptors. During embryogenesis, VEGF-C may play a role in the formation of the venous and lymphatic vascular systems. Both VEGF-C and VEGF-D are over-expressed in certain cancers, and the resulting elevated levels of VEGF-C or VEGF-D tend to correlate with increased lymphatic metastasis. Recombinant, fully processed rat VEGF-C is a 16-18 kDa non-disulfide linked homodimeric protein consisting of two 116 amino acid polypeptide chains. Due to glycosylation the protein migrates as a 20.0-22.0 kDa band under non-reducing condition.

Anti-Rat VEGF-D Antibody

104-PA12S 100 µg
EUR 115.5
Description: Vascular endothelial growth factor D (VEGF-D), also known as C-fos induced growth factor (FIGF), is a vascular endothelial growth factor. This secreted protein is a member of the platelet derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family and performs activities in angiogenesis, lymphangiogenesis, and endothelial cell growth. Human VEGF-D is expressed in adult lung, heart, muscle, and small intestine, and is most abundantly expressed in fetal lungs and skin. It is structurally and functionally similar to VEGF-C, and is secreted as a non-covelent homodimer in a antiparallel fashion. VEGF-D undergoes a complex proteolytic maturation, generating multiple processed forms which bind and activate VEGFR-2 and VEGFR-3 receptors. Like VEGFC, it may particularly be involed in the formation of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults.

Anti-Rat VEGF-C Antibody

104-PABi10 50 µg
EUR 157.5
Description: VEGF-C, a member of the VEGF/PDGF family of structurally related proteins, is a potent angiogenic cytokine. It promotes endothelial cell growth, promotes lymphangiogesis, and can also affect vascular permeability. VEGF-C is expressed in various tissues, but is not produced in peripheral blood lymphocytes. It forms cell surfaced-associated non-covalent disulfide linked homodimers, and can bind and activate both VEGFR-2 (flk1) and VEGFR-3 (flt4) receptors. During embryogenesis, VEGF-C may play a role in the formation of the venous and lymphatic vascular systems. Both VEGF-C and VEGF-D are over-expressed in certain cancers, and the resulting elevated levels of VEGF-C or VEGF-D tend to correlate with increased lymphatic metastasis. Recombinant, fully processed rat VEGF-C is a 16-18 kDa non-disulfide linked homodimeric protein consisting of two 116 amino acid polypeptide chains. Due to glycosylation the protein migrates as a 20.0-22.0 kDa band under non-reducing condition.

Anti-bovine VEGF-A PAb

GWB-QIUF78 1 kit Ask for price

Anti-bovine VEGF-A PAb

GWB-W4HYD7 1 kit Ask for price

Anti-equine VEGF-A PAb

GWB-KI0037 1 kit Ask for price

Rabbit anti VEGF-A (human)

102-PA02S 100ug
EUR 240

Rabbit anti VEGF-A (human)

102-PA03AG 50ug
EUR 240

Rabbit anti VEGF-A (mouse)

103-PA03AG 50ug
EUR 297.6

Rabbit anti VEGF-A (mouse)

103-PA03S 100ug
EUR 240

Anti-Human VEGF-A Antibody

101-M57 100 µg
EUR 399
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors.

Anti-Human VEGF-A Antibody

101-M60 100 µg
EUR 173.25
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors.

Anti-Human VEGF-B Antibody

101-M62 100 µg
EUR 399
Description: VEGF-B, a member of the VEGF family, is a potent growth and angiogenic cytokine. It promotes DNA synthesis in endothelial cells, helps regulate angiogenesis and vascular permeability, and inhibits apoptosis in certain smooth muscle cells and neurons. VEGF-B is expressed in all tissues except the liver. It forms cell surfaced-associated disulfide linked homodimers and can form heterodimers with VEGF-A. There are two known isoforms, formed by alternative splicing, which have been designated VEGF-B167 and VEGF-B186. Both forms have identical amino-terminal sequences encoding a “cysteine knot” like structural motif, but differ in their carboxyl-terminal domains. Both VEGF-B isoforms signal only through the VEGFR1 receptor. Recombinant human VEGF-B is a 38.0 kDa disulfide-linked homodimeric protein consisting of two 167 amino acid polypeptide chains.

Anti-Human VEGF-C Antibody

101-M64 100 µg
EUR 399
Description: VEGF-C, a member of the VEGF/PDGF family of structurally related proteins, is a potent angiogenic cytokine. It promotes endothelial cell growth, promotes lymphangiogesis, and can also affect vascular permeability. VEGF-C is expressed in various tissues, but is not produced in peripheral blood lymphocytes. It forms cell surfaced-associated non-covalent disulfide linked homodimers, and can bind and activate both VEGFR-2 (flk1) and VEGFR-3 (flt4) receptors. During embryogenesis, VEGF-C may play a role in the formation of the venous and lymphatic vascular systems. Both VEGF-C and VEGF-D are over-expressed in certain cancers, and the resulting elevated levels of VEGF-C or VEGF-D tend to correlate with increased lymphatic metastasis. Recombinant, fully processed human VEGF-C is a 13.5 kDa non-disulfide linked homodimeric protein consisting of two 116 amino acid polypeptide chains. Due to glycosylation the protein migrates as a 20.0-22.0 kDa band under non-reducing condition.

Anti-Human VEGF-D Antibody

101-M66 100 µg
EUR 399
Description: VEGF-D, a member of the VEGF/PDGF family of structurally related proteins, is a potent angiogenic cytokine. It promotes endothelial cell growth, promotes lymphangiogesis, and can also affect vascular permeability. VEGF-D is highly expressed in the lung, heart, small intestine and fetal lung, and at lower levels in the skeletal muscle, colon, and pancreas. It forms cell surfaced-associated non-covalent disulfide linked homodimers, and can bind and activate both VEGFR-2 (flk1) and VEGFR-3 (flt4) receptors. During embryogenesis, VEGF-D may play a role in the formation of the venous and lymphatic vascular systems. It also participates in the growth and maintenance of differentiated lymphatic endothelium in adults. Both VEGF-C and VEGF-D are over-expressed in certain cancers, and the resulting elevated levels of VEGF-C or VEGF-D tend to correlate with increased lymphatic metastasis.

Anti-Human VEGF-A Antibody

101-M855 100 µg
EUR 399
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors.

Anti-Human VEGF-B Antibody

101-M856 100 µg
EUR 399
Description: VEGF-B, a member of the VEGF family, is a potent growth and angiogenic cytokine. It promotes DNA synthesis in endothelial cells, helps regulate angiogenesis and vascular permeability, and inhibits apoptosis in certain smooth muscle cells and neurons. VEGF-B is expressed in all tissues except the liver. It forms cell surfaced-associated disulfide linked homodimers and can form heterodimers with VEGF-A. There are two known isoforms, formed by alternative splicing, which have been designated VEGF-B167 and VEGF-B186. Both forms have identical amino-terminal sequences encoding a “cysteine knot” like structural motif, but differ in their carboxyl-terminal domains. Both VEGF-B isoforms signal only through the VEGFR1 receptor. Recombinant human VEGF-B is a 38.0 kDa disulfide-linked homodimeric protein consisting of two 167 amino acid polypeptide chains.

Anti-Human VEGF-B Antibody

101-M857 100 µg
EUR 399
Description: VEGF-B, a member of the VEGF family, is a potent growth and angiogenic cytokine. It promotes DNA synthesis in endothelial cells, helps regulate angiogenesis and vascular permeability, and inhibits apoptosis in certain smooth muscle cells and neurons. VEGF-B is expressed in all tissues except the liver. It forms cell surfaced-associated disulfide linked homodimers and can form heterodimers with VEGF-A. There are two known isoforms, formed by alternative splicing, which have been designated VEGF-B167 and VEGF-B186. Both forms have identical amino-terminal sequences encoding a “cysteine knot” like structural motif, but differ in their carboxyl-terminal domains. Both VEGF-B isoforms signal only through the VEGFR1 receptor. Recombinant human VEGF-B is a 38.0 kDa disulfide-linked homodimeric protein consisting of two 167 amino acid polypeptide chains.

Anti-Human VEGF-B Antibody

101-M858 100 µg
EUR 399
Description: VEGF-B, a member of the VEGF family, is a potent growth and angiogenic cytokine. It promotes DNA synthesis in endothelial cells, helps regulate angiogenesis and vascular permeability, and inhibits apoptosis in certain smooth muscle cells and neurons. VEGF-B is expressed in all tissues except the liver. It forms cell surfaced-associated disulfide linked homodimers and can form heterodimers with VEGF-A. There are two known isoforms, formed by alternative splicing, which have been designated VEGF-B167 and VEGF-B186. Both forms have identical amino-terminal sequences encoding a “cysteine knot” like structural motif, but differ in their carboxyl-terminal domains. Both VEGF-B isoforms signal only through the VEGFR1 receptor. Recombinant human VEGF-B is a 38.0 kDa disulfide-linked homodimeric protein consisting of two 167 amino acid polypeptide chains.

Anti-Human VEGF-D Antibody

101-M859 100 µg
EUR 399
Description: VEGF-D, a member of the VEGF/PDGF family of structurally related proteins, is a potent angiogenic cytokine. It promotes endothelial cell growth, promotes lymphangiogesis, and can also affect vascular permeability. VEGF-D is highly expressed in the lung, heart, small intestine and fetal lung, and at lower levels in the skeletal muscle, colon, and pancreas. It forms cell surfaced-associated non-covalent disulfide linked homodimers, and can bind and activate both VEGFR-2 (flk1) and VEGFR-3 (flt4) receptors. During embryogenesis, VEGF-D may play a role in the formation of the venous and lymphatic vascular systems. It also participates in the growth and maintenance of differentiated lymphatic endothelium in adults. Both VEGF-C and VEGF-D are over-expressed in certain cancers, and the resulting elevated levels of VEGF-C or VEGF-D tend to correlate with increased lymphatic metastasis.

Anti-Human VEGF-C Antibody

101-M88 100 µg
EUR 189
Description: VEGF-C, also known as Vascular Endothelial Growth Factor Related Protein (VRP), is a recently discovered VEGF growth factor family member that is most closely related to VEGF-D. The human VEGF-C cDNA encodes a pre-pro-protein of 416 amino acids residues. It is almost identical to the mouse VEGF-C protein. Similar to VEGF-D, VEGF-C has a VEGF homology domain spanning the middle third of the precursor molecule and long N- and C-terminal extensions. In adults, VEGF-C is highly expressed in heart, placenta, ovary and small intestine. Recombinant human VEGF-C, lacking the N- and C-terminal extensions and containing only the middle VEGF homology domain, forms primarily non-covalently linked dimers. This protein is a ligand for both VEGFR-2/KDR and VEGFR-3/FLT-4. Since VEGFR-3 is strongly expressed in lymphatic endothelial cells, it has been postulated that VEGF-C is involved in the regulation of the growth and/or differentiation of lymphatic endothelium. Although recombinant human VEGF-C is also a mitogen for vascular endothelial cells, it is much less potent than VEGF-A. The recombinant human VEGF-C contains 115 amino acids residues and was fused to a His-tag (6x His) at the C-terminal end. As a result of glycosylation VEGF-C migrates as an 18-24 kDa protein in SDS-PAGE under reducing conditions.

Anti-Human VEGF-C Antibody

101-M89 100 µg
EUR 189
Description: VEGF-C, also known as Vascular Endothelial Growth Factor Related Protein (VRP), is a recently discovered VEGF growth factor family member that is most closely related to VEGF-D. The human VEGF-C cDNA encodes a pre-pro-protein of 416 amino acids residues. It is almost identical to the mouse VEGF-C protein. Similar to VEGF-D, VEGF-C has a VEGF homology domain spanning the middle third of the precursor molecule and long N- and C-terminal extensions. In adults, VEGF-C is highly expressed in heart, placenta, ovary and small intestine. Recombinant human VEGF-C, lacking the N- and C-terminal extensions and containing only the middle VEGF homology domain, forms primarily non-covalently linked dimers. This protein is a ligand for both VEGFR-2/KDR and VEGFR-3/FLT-4. Since VEGFR-3 is strongly expressed in lymphatic endothelial cells, it has been postulated that VEGF-C is involved in the regulation of the growth and/or differentiation of lymphatic endothelium. Although recombinant human VEGF-C is also a mitogen for vascular endothelial cells, it is much less potent than VEGF-A. The recombinant human VEGF-C contains 115 amino acids residues and was fused to a His-tag (6x His) at the C-terminal end. As a result of glycosylation VEGF-C migrates as an 18-24 kDa protein in SDS-PAGE under reducing conditions.

Anti-Human VEGF-C Antibody

101-M90 100 µg
EUR 189
Description: VEGF-C, also known as Vascular Endothelial Growth Factor Related Protein (VRP), is a recently discovered VEGF growth factor family member that is most closely related to VEGF-D. The human VEGF-C cDNA encodes a pre-pro-protein of 416 amino acids residues. It is almost identical to the mouse VEGF-C protein. Similar to VEGF-D, VEGF-C has a VEGF homology domain spanning the middle third of the precursor molecule and long N- and C-terminal extensions. In adults, VEGF-C is highly expressed in heart, placenta, ovary and small intestine. Recombinant human VEGF-C, lacking the N- and C-terminal extensions and containing only the middle VEGF homology domain, forms primarily non-covalently linked dimers. This protein is a ligand for both VEGFR-2/KDR and VEGFR-3/FLT-4. Since VEGFR-3 is strongly expressed in lymphatic endothelial cells, it has been postulated that VEGF-C is involved in the regulation of the growth and/or differentiation of lymphatic endothelium. Although recombinant human VEGF-C is also a mitogen for vascular endothelial cells, it is much less potent than VEGF-A. The recombinant human VEGF-C contains 115 amino acids residues and was fused to a His-tag (6x His) at the C-terminal end. As a result of glycosylation VEGF-C migrates as an 18-24 kDa protein in SDS-PAGE under reducing conditions.

Anti-Human VEGF-C Antibody

101-M91 100 µg
EUR 189
Description: VEGF-C, also known as Vascular Endothelial Growth Factor Related Protein (VRP), is a recently discovered VEGF growth factor family member that is most closely related to VEGF-D. The human VEGF-C cDNA encodes a pre-pro-protein of 416 amino acids residues. It is almost identical to the mouse VEGF-C protein. Similar to VEGF-D, VEGF-C has a VEGF homology domain spanning the middle third of the precursor molecule and long N- and C-terminal extensions. In adults, VEGF-C is highly expressed in heart, placenta, ovary and small intestine. Recombinant human VEGF-C, lacking the N- and C-terminal extensions and containing only the middle VEGF homology domain, forms primarily non-covalently linked dimers. This protein is a ligand for both VEGFR-2/KDR and VEGFR-3/FLT-4. Since VEGFR-3 is strongly expressed in lymphatic endothelial cells, it has been postulated that VEGF-C is involved in the regulation of the growth and/or differentiation of lymphatic endothelium. Although recombinant human VEGF-C is also a mitogen for vascular endothelial cells, it is much less potent than VEGF-A. The recombinant human VEGF-C contains 115 amino acids residues and was fused to a His-tag (6x His) at the C-terminal end. As a result of glycosylation VEGF-C migrates as an 18-24 kDa protein in SDS-PAGE under reducing conditions.

Anti-Human VEGF-A Antibody

101-MBi60 50 µg
EUR 173.25
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors.

Anti-Human VEGF-C Antibody

101-MBi89 50 µg
EUR 189
Description: VEGF-C, also known as Vascular Endothelial Growth Factor Related Protein (VRP), is a recently discovered VEGF growth factor family member that is most closely related to VEGF-D. The human VEGF-C cDNA encodes a pre-pro-protein of 416 amino acids residues. It is almost identical to the mouse VEGF-C protein. Similar to VEGF-D, VEGF-C has a VEGF homology domain spanning the middle third of the precursor molecule and long N- and C-terminal extensions. In adults, VEGF-C is highly expressed in heart, placenta, ovary and small intestine. Recombinant human VEGF-C, lacking the N- and C-terminal extensions and containing only the middle VEGF homology domain, forms primarily non-covalently linked dimers. This protein is a ligand for both VEGFR-2/KDR and VEGFR-3/FLT-4. Since VEGFR-3 is strongly expressed in lymphatic endothelial cells, it has been postulated that VEGF-C is involved in the regulation of the growth and/or differentiation of lymphatic endothelium. Although recombinant human VEGF-C is also a mitogen for vascular endothelial cells, it is much less potent than VEGF-A. The recombinant human VEGF-C contains 115 amino acids residues and was fused to a His-tag (6x His) at the C-terminal end. As a result of glycosylation VEGF-C migrates as an 18-24 kDa protein in SDS-PAGE under reducing conditions.

Anti-Human VEGF-A Antibody

102-P91 100 µg
EUR 245.7
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors.

Anti-Human VEGF-A Antibody

102-P91G 100 µg
EUR 245.7
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors.

Anti-Human VEGF-A Antibody

102-PA02 200 µg
EUR 147
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. The antibody is against the N-terminus and will recognize all VEGF-A isoforms.

Anti-Human VEGF-B Antibody

102-PA72S 100 µg
EUR 126
Description: Vascular endothelial growth factor B (VEGF-B), also known as vascular endothelial growth factor-related factor (VRF), is a member of the VEGF family of growth factors that share structural and functional similarity. Five mammalian members, including VEGF-A, B, C, D and PlGF, have been identified. VEGF family members are disulfide-linked dimeric proteins that are important regulators of physiological and pathological vasculogenesis, angiogenesis and lymphangiogenesis. VEGF-B is expressed in most tissues, especially in heart, skeletal muscle and pancreas. In many tissues, VEGF-B is coexpressed and can heterodimerize with VEGF. By alternative splicing, two isoforms of mature VEGF-B containing 167 or 186 amino acid (aa) residues exist. The two VEGF-B isoforms have identical amino-terminal cysteine knot VEGF homology domains but the carboxyl end of VEGF-B167 differs from that of VEGF-B186 by the presence of a highly basic cysteine-rich heparin binding domain. Whereas VEGF-B186 is a secreted diffusible protein, VEGF-B167 is sequestered into the cell matrix after secretion. Both VEGF-B isoforms bind VEGF receptor 1 (VEGFR-1), but not VEGFR-2 or VEGFR-3. On endothelial cells, ligation of VEGFR-1 by VEGF-B has been shown to regulate the expression and activity of urokinase type plasminogen activator and plasminogen activator inhibitor 1. VEGF-B167 and a proteolytically processed form of VEGF-B186 (VEGF-B127) also bind neuropilin1 (NP1), a type I transmembrane receptor for semaphorins/collapsins, ligands involved in neuron guidance (6). Besides VEGF-B, NP1 has been shown to bind PlGF-2, VEGF165 and VEGFR-1. The many interactions of NP1 with VEGF ligands and receptor suggest that NP1 may function as a regulator of angiogenesis.

Anti-Mouse VEGF-A Antibody

103-M57 100 µg
EUR 399
Description: Mouse VEGF is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant murine VEGF (isoform 164) is a 39.0 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains.

Anti-Mouse VEGF-A Antibody

103-M57A 100 µg
EUR 399
Description: Mouse VEGF is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant murine VEGF (isoform 164) is a 39.0 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains.

Anti-Mouse VEGF-B Antibody

103-M62 100 µg
EUR 399
Description: Vascular endothelial growth factor B (VEGF-B), also known as vascular endothelial growth factor-related factor (VRF), is a member of the VEGF family of growth factors that share structural and functional similarity.

Anti-Mouse VEGF-D Antibody

103-M66 100 µg
EUR 399
Description: VEGF-D, a member of the VEGF/PDGF family of structurally related proteins, is a potent angiogenic cytokine. It promotes endothelial cell growth, promotes lymphangiogesis, and can also affect vascular permeability. VEGF-D is highly expressed in the lung, heart, small intestine and fetal lung, and at lower levels in the skeletal muscle, colon, and pancreas. It forms cell surfaced-associated non-covalent disulfide linked homodimers, and can bind and activate both VEGFR-2 (flk1) and VEGFR-3 (flt4) receptors. During embryogenesis, VEGF-D may play a role in the formation of the venous and lymphatic vascular systems. It also participates in the growth and maintenance of differentiated lymphatic endothelium in adults. Both VEGF-C and VEGF-D are over-expressed in certain cancers, and the resulting elevated levels of VEGF-C or VEGF-D tend to correlate with increased lymphatic metastasis.

Anti-Mouse VEGF-A Antibody

103-P36 100 µg
EUR 245.7
Description: Mouse VEGF is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant murine VEGF (isoform 164) is a 39.0 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains.

Anti-Mouse VEGF-A Antibody

103-PA03 200 µg
EUR 246.75
Description: Mouse VEGF is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant murine VEGF (isoform 164) is a 39.0 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains.

Anti-Mouse VEGF-A Antibody

103-PABi03 50 µg
EUR 157.5
Description: Mouse VEGF is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant murine VEGF (isoform 164) is a 39.0 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains.

Anti-mouse VEGF(Rat) Antibody

Y052991 100 µg
EUR 695

mouse anti-human VEGF mAb

E409C31-m100 100μL
EUR 395
Description: Available in various conjugation types.

Rat Monoclonal anti-mouse VEGF 164

mAP-0009A 100ug
EUR 250

Anti-Human VEGF Purified Ab

E16THU007-050 50Tests
EUR 145
Description: Available in various conjugation types.

Anti-Human VEGF Purified Ab

E16THU007-100 100Tests
EUR 225
Description: Available in various conjugation types.

Mouse Monoclonal anti-human VEGF-165b

hAP-0051 100ug
EUR 250

Rabbit Anti-Human VEGF-B167

102-PA72 100ug
EUR 240

Humanized anti-human VEGF antibody

APT-0002 1Service Ask for price

Rat Monoclonal anti-mouse VEGF

mAP-0009 100ug
EUR 250

Rabbit Anti-Human VEGF Polyclonal

SPC-1291D 0.1ml
EUR 286
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is unconjugated.

Rabbit Anti-Human VEGF Polyclonal

SPC-1291D-A390 0.1ml
EUR 340
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to ATTO 390.

Rabbit Anti-Human VEGF Polyclonal

SPC-1291D-A488 0.1ml
EUR 339
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to ATTO 488.

Rabbit Anti-Human VEGF Polyclonal

SPC-1291D-A594 0.1ml
EUR 339
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to ATTO 594.

Rabbit Anti-Human VEGF Polyclonal

SPC-1291D-BI 0.1ml
EUR 334
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to Biotin.

Rabbit Anti-Human VEGF Polyclonal

SPC-1291D-FITC 0.1ml
EUR 330
Description: A polyclonal antibody for VEGF from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with human synthetic peptide corresponding to a region derived human vascular endothelial growth factor A. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:1000), IHC (1:200). This VEGF antibody is conjugated to FITC.

Mouse anti VEGF-A (#3) (human)

101-M59 100ug
EUR 297.6

Mouse anti VEGF-A (#3C5) (human)

101-M56 100ug
EUR 297.6

Mouse anti VEGF-A (#7G7) (human)

101-M58 100ug
EUR 297.6

VEGF-A(VEGF/1063), 0.2mg/mL

BNUB1063-100 100uL
EUR 225
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

VEGF-A(VEGF/1063), 0.2mg/mL

BNUB1063-500 500uL
EUR 485
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

VEGF-A(VEGF/1063), 1mg/mL

BNUM1063-50 50uL
EUR 396
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application

human anti-human VEGF mAb(1C)

E4A09D12-A1C 50ug
EUR 255
Description: Available in various conjugation types.

human anti-human VEGF mAb(9D)

E4A09D12-B9D 50ug
EUR 255
Description: Available in various conjugation types.

human anti-human VEGF mAb(46)

E4A09D12-46 50ug
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

human anti-human VEGF mAb(47)

E4A09D12-47 50ug
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

human anti-human VEGF mAb(52)

E4A09D12-52 50ug
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

human anti-human VEGF mAb(57)

E4A09D12-57 50ug
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

human anti-human VEGF mAb(6A)

E4A09D12-6A 50ug
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

human anti-human VEGF mAb(6C)

E4A09D12-6C 50ug
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

human anti-human VEGF mAb(6E)

E4A09D12-6E 50ug
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

Rabbit anti VEGF-A pan (human)

102-PA03S 100ug
EUR 240

Anti-Orf Virus VEGF-E Antibody

102-PA70 50 µg
EUR 115.5
Description: A DNA sequence encoding the mature variant of ov-VEGF-E isolate D1701 was expressed in E. coli as a 132 amino acid residue fusion protein with an N-terminal His-tag sequence and a thrombin cleavage site. Recombinant VEGF-E homodimer was dimerized in vitro and has a predicted mass of approximately 35 kDa. Based on sequence similarity to VEGF-A, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV). Different isolates of Orf virus show significant amino acid sequence similarity to VEGF-A and described as a viral virulence factor that appears to be derived from captured host genes. All eight Cysteine residues of the central Cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGF-E proteins. Alignment of all mammalian VEGF sequences indicated that VEGF-E is distinct from the previously described VEGFs but most closely related to VEGF-A. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGF-A, VEGF-E cannot bind to VEGF receptor-1 (Flt-1). Furthermore VEGF-E can also not bind to VEGF receptor-3 (FLT-4). Therefore VEGF-E is a potent angiogenic factor selectively binding to VEGF receptor –2/KDR.

VEGF/ Rat VEGF ELISA Kit

ELA-E0143r 96 Tests
EUR 1063.2

VEGF Antibody

5363-100 each
EUR 398.4

VEGF Antibody

5363-30T each
EUR 175.2

VEGF Antibody

5365-100 each
EUR 379.2

VEGF Antibody

5365-30T each
EUR 175.2

VEGF antibody

10-2585 250 ug
EUR 590.4
Description: Mouse monoclonal VEGF antibody

VEGF antibody

10-2586 100 ug
EUR 289.2
Description: Mouse monoclonal VEGF antibody

VEGF antibody

10R-V101ax 100 ug
EUR 571.2
Description: Mouse monoclonal VEGF antibody

VEGF antibody

10R-V101b 200 ug
EUR 805.2
Description: Mouse monoclonal VEGF antibody

VEGF antibody

10R-V109A 500 ug
EUR 240
Description: Mouse monoclonal VEGF antibody

VEGF antibody

10R-7735 500 ug
EUR 678
Description: Mouse monoclonal VEGF antibody

VEGF Antibody

48707 100ul
EUR 499

VEGF Antibody

48707-100ul 100ul
EUR 399.6

VEGF Antibody

48707-50ul 50ul
EUR 286.8

VEGF Antibody

E18-5131-1 50μg/50μl
EUR 145
Description: Available in various conjugation types.

VEGF Antibody

E18-5131-2 100μg/100μl
EUR 225
Description: Available in various conjugation types.

VEGF Antibody

E8ER30607 100ul
EUR 225
Description: Available in various conjugation types.

VEGF Antibody

E8RT1649 100ul
EUR 225
Description: Available in various conjugation types.

VEGF Antibody

E90126 100ug
EUR 255
Description: Available in various conjugation types.

VEGF Antibody

E3M00036 200ul
EUR 275
Description: Available in various conjugation types.

VEGF Antibody

E3M00102 200ul
EUR 275
Description: Available in various conjugation types.

VEGF Antibody

E301007 200ul
EUR 275
Description: Available in various conjugation types.

VEGF antibody

CAF50370-100ug 100ug
EUR 338

VEGF antibody

CAF50643-100ug 100ug
EUR 364

VEGF antibody

70R-12327 100 ug
EUR 364
Description: Rabbit polyclonal VEGF antibody

VEGF antibody

70R-12328 100 ug
EUR 343
Description: Rabbit polyclonal VEGF antibody

VEGF antibody

70R-12329 100 ug
EUR 343
Description: Rabbit polyclonal VEGF antibody

VEGF antibody

70R-13764 100 ug
EUR 578
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody

70R-11863 100 ul
EUR 375
Description: Goat polyclonal VEGF antibody

VEGF antibody

70R-11864 100 ug
EUR 343
Description: Rabbit polyclonal VEGF antibody

VEGF antibody

70-VR20 50 ug
EUR 312
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody

70R-VR004 50 ug
EUR 312
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody

70R-VR006 50 ug
EUR 312
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody

70R-VG001 100 ug
EUR 312
Description: Affinity purified Goat polyclonal VEGF antibody

VEGF antibody

70R-VR001x 50 ug
EUR 312
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF antibody

70R-VR003 50 ug
EUR 312
Description: Affinity purified Rabbit polyclonal VEGF antibody

VEGF Antibody

ABF5131 100 ug
EUR 525.6

VEGF, Antibody

GWB-5F48B1 7 ml Ask for price

VEGF Antibody

GWB-2184EB 0.1 mg Ask for price

VEGF Antibody

GWB-88861F 0.5 ml Ask for price

VEGF Antibody

GWB-AA0FA3 0.5 ml Ask for price

VEGF Antibody

GWB-7D2F87 0.1 mg Ask for price

VEGF, Antibody

GWB-F61EF9 7 ml Ask for price

VEGF Antibody

GWB-E45680 0.5 ml Ask for price

VEGF Antibody

GWB-E54BC7 0.25 ml Ask for price

VEGF, Antibody

GWB-C4E434 1 ml Ask for price

VEGF antibody

PAab09933 100 ug
EUR 463.2

VEGF Antibody

R31500 100 ug
EUR 356.15
Description: VEGF is the only mitogen that specifically acts on endothelial cells. It may be a major regulator of tumor angiogenesis in vivo. It is structurally related to platelet-derived growth factor. VEGF shares homology with the PDGF A chain and B chain, including conservation of all 8 cysteines found in PDGFA and PDGFB. VEGF gene contains 8 exons. VEGF induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. And this gene also can regulate haematopoietic stem cell survival by an internal autocrine loop mechanism. What’s more, it also stimulates neurogenesis in vitro and in vivo.

VEGF Antibody

V8154-100UG 100 ug
EUR 424.15
Description: This mAb recognizes proteins of 19-22kDa (reducing) and 38kDa-44kDa (non-reducing), identified as various isoforms of Vascular Endothelial Growth Factor or Vascular Permeability Factor (VEGF/VPF). It is highly specific to VEGF, which is a homodimeric, disulfide-linked glycoprotein with a close homology to platelet-derived growth factor (PDGF). There are multiple isoforms of VEGF containing 206-, 189-, 165-, and 121-amino acid residues. The smaller two isoforms, VEGF165 and VEGF121, are secreted proteins and act as diffusible agents, whereas the larger two remain cell associated. VEGF/VPF plays an important role in angiogenesis, which promotes tumor progression and metastasis.

VEGF Antibody

V8154-20UG 20 ug
EUR 186.15
Description: This mAb recognizes proteins of 19-22kDa (reducing) and 38kDa-44kDa (non-reducing), identified as various isoforms of Vascular Endothelial Growth Factor or Vascular Permeability Factor (VEGF/VPF). It is highly specific to VEGF, which is a homodimeric, disulfide-linked glycoprotein with a close homology to platelet-derived growth factor (PDGF). There are multiple isoforms of VEGF containing 206-, 189-, 165-, and 121-amino acid residues. The smaller two isoforms, VEGF165 and VEGF121, are secreted proteins and act as diffusible agents, whereas the larger two remain cell associated. VEGF/VPF plays an important role in angiogenesis, which promotes tumor progression and metastasis.

VEGF Antibody

V8154SAF-100UG 100 ug
EUR 424.15
Description: This mAb recognizes proteins of 19-22kDa (reducing) and 38kDa-44kDa (non-reducing), identified as various isoforms of Vascular Endothelial Growth Factor or Vascular Permeability Factor (VEGF/VPF). It is highly specific to VEGF, which is a homodimeric, disulfide-linked glycoprotein with a close homology to platelet-derived growth factor (PDGF). There are multiple isoforms of VEGF containing 206-, 189-, 165-, and 121-amino acid residues. The smaller two isoforms, VEGF165 and VEGF121, are secreted proteins and act as diffusible agents, whereas the larger two remain cell associated. VEGF/VPF plays an important role in angiogenesis, which promotes tumor progression and metastasis.

Rat Monoclonal anti-mouse VEGF-D

mAP-0007 100ug
EUR 250

 

Engineering a novel IgG-like bispecific antibody towards enterovirus A71

 

Frequent outbreaks of enterovirus A71 (EVA71) happen within the Asia-Pacific space, and these are carefully related to extreme neurological signs in younger kids. No efficient antiviral remedy is at present accessible for the therapy of EVA71 an infection. The event of monoclonal antibodies (mAbs) has demonstrated promise as a novel remedy for the prevention and therapy of infectious illnesses. A number of medical situations have been handled utilizing bispecific or multi-specific antibodies that acknowledge two or extra distinct epitopes concurrently. Nevertheless, bispecific or multi-specific antibodies typically encounter protein expression and product stability issues.

On this research, we developed an IgG-like bispecific antibody (E18-F1) comprising two anti-EVA71 antibodies: E18 mAb and llama-derived F1 single-domain antibody. E18-F1 was demonstrated to exhibit superior binding affinity and antiviral exercise in contrast with E18 or F1. Moreover, E18-F1 not solely improved survival price, but in addition decreased medical indicators in human SCARB2 receptor (hSCARB2) transgenic mice challenged with a deadly dose of EVA71. Altogether, our outcomes reveal that E18-F1 is a straightforward format bispecific antibody with promising antiviral exercise for EVA71.

Excessive antibody ranges towards human herpesvirus-6A work together with life-style elements in a number of sclerosis growth

 

Background: An infection with human herpesvirus 6A (HHV-6A) has been instructed to extend a number of sclerosis (MS) danger. Nevertheless, potential interactions between HHV-6A and environmental/life-style danger elements for MS haven’t beforehand been studied.

Strategies: We used two Swedish population-based case-control research comprising 5993 circumstances and 5995 controls. Utilizing logistic regression fashions, topics with completely different HHV-6A antibody ranges, environmental exposures, and life-style habits have been in contrast concerning MS danger, by calculating odds ratios (ORs) with 95% confidence intervals (CIs). Potential interactions between excessive HHV-6A antibody ranges and customary environmental exposures and life-style elements have been evaluated on the additive scale.

Outcomes: Excessive HHV-6A antibody ranges have been related to elevated danger of creating MS (OR = 1.5, 95% CI = 1.4-1.6). Concerning MS danger, vital interactions have been noticed between excessive HHV-6A antibody ranges and each smoking (attributable proportion (AP) = 0.2, 95% CI = 0.1-0.3), low ultraviolet radiation (UVR) publicity (AP = 0.3, 95% CI = 0.1-0.4), and low vitamin D ranges (AP = 0.3, 95% CI = 0.0-0.6).

Conclusion: Excessive HHV-6A antibody ranges are related to elevated MS danger and act synergistically with widespread environmental/life-style danger elements for MS. Additional analysis is required to analyze potential mechanisms underlying the interactions introduced on this research.

 

Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *